Blood-brain barrier transport of short proline-rich antimicrobial peptides

Protein and Peptide Letters

Volumn 21, Issue 4, 2014, Pages 399-406

  Stalmans, Sofie ^a   Wynendaele, Evelien ^a   Bracke, Nathalie ^a   Knappe, Daniel ^b,c   Hoffmann, Ralf ^b,c   Peremans, Kathelijne ^a   Polis, Ingeborgh ^a   Burvenich, Christian ^a   De Spiegeleer, Bart ^a  

^a GHENT UNIVERSITY   (Belgium)

^b Faculty of Chemistry and Mineralogy   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antimicrobial peptides; Bio distribution; Blood brain barrier; Cell penetrating peptides; In vivo; Stability; Transport

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE RICH ANTIMICROBIAL PEPTIDE API137; PROLINE RICH ANTIMICROBIAL PEPTIDE DROSOCIN; PROLINE RICH ANTIMICROBIAL PEPTIDE DROSOCIN PROLINE 5 HYDROXYPROLINE; PROLINE RICH ANTIMICROBIAL PEPTIDE ONCOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFECTION; BRAIN SIZE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG TRANSPORT; ENDOTHELIUM CELL; FLOW RATE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARENCHYMA; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD-BRAIN BARRIER; BRAIN; GLYCOPEPTIDES; HUMANS; INSECT PROTEINS; MALE; MICE; MOLECULAR SEQUENCE DATA;

EID: 84896327594     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113206660110     Document Type: Article

References (33)

1. Spellberg, B.; Bartlett, J.G.; Gilbert, D.N. The Future of Antibiotics and Resistance. N. Eng. J. Med., 2013, 368(4), 299-302.
2. Otvos, L. Jr. The short proline-rich antibacterial peptide family. Cell. Mol. Life Sci., 2002, 59(7), 1138-1150.
3. Li, Y.; Xiang, Q.; Zhang, Q.; Huang, Y.; Su, Z. Overview on the recent study of antimicrobial peptides: Origins, functions, relative mechanisms and application. Peptides, 2012, 37(2), 207-215.
4. Scocchi, M.; Tossi, A.; Gennaro, R. Proline-rich antimicrobial peptides: converging to a non-lytic mechanism of action. Cell. Mol. Life Sci., 2011, 68(13), 2317-2330.
5. Otvos, L. Jr.; O, I.; Rogers, M.E.; Consolvo, P.J.; Condie, B.A.; Lovas, S.; Bulet, P.; Blaszczyk-Thurin, M. Interaction between Heat Shock Proteins and Antimicrobial Peptides. Biochemistry, 2000, 39(46), 14150-14159.
6. Berthold, N.; Czihal, P.; Fritsche, S.; Sauer, U.; Schiffer, G.; Knappe, D.; Alber, G.; Hoffmann, R. Novel Apidaecin 1b Analogs with Superior Serum Stabilities for Treatment of Infections by Gram-Negative Pathogens. Antimicrob. Agents Ch., 2013, 57(1), 402-409.
7. Knappe, D.; Piantavigna, S.; Hansen, A.; Mechler, A.; Binas, A.; Nolte, O.; Martin, L.L.; Hoffmann, R. Oncocin (VDKPPYLP RPRPPRRIYNR-NH2): A Novel Antibacterial Peptide Optimized against Gram-Negative Human Pathogens. J. Med. Chem., 2010, 53(14), 5240-5247.
8. Hansen, A.; Schäfer, I.; Knappe, D.; Seibel, P.; Hoffmann, R. Intracellular Toxicity of Proline-Rich Antimicrobial Peptides Shuttled into Mammalian Cells by the Cell-Penetrating Peptide Penetratin. Antimicrob. Agents Chemother., 2012, 56(10), 5194-5201.
9. Karampekios, S.; Hesselink, J. Cerebral infections. Eur. Radiol., 2005, 15(3), 485-493.
10. Kim, K.S. Treatment strategies for central nervous system infections. Expert Opin. Pharmacother., 2009, 10(8), 1307-1317.
11. Abbott, N.J.; Patabendige, A.A.K.; Dolman, D.E.M.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25.
12. Czihal, P.; Knappe, D.; Fritsche, S.; Zahn, M.; Berthold, N.; Piantavigna, S.; Müller, U.; Van Dorpe, S.; Herth, N.; Binas, A.; Köhler, G.; De Spiegeleer, B.; Martin, L.L.; Nolte, O.; Sträter, N.; Alber, G.; Hoffmann, R. Api88 Is a Novel Antibacterial Designer Peptide To Treat Systemic Infections with Multidrug-Resistant Gram-Negative Pathogens. ACS Chem. Biol., 2012, 7(7), 1281-1291.
13. Rousselle, C.; Clair, P.; Lefauconnier, J.-M.; Kaczorek, M.; Scherrmann, J.-M.; Temsamani, J. New Advances in the Transport of Doxorubicin through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy. Mol. Pharmacol., 2000, 57(4), 679-686.
14. Rousselle, C.; Smirnova, M.; Clair, P.; Lefauconnier, J.-M.; Chavanieu, A.; Calas, B.; Scherrmann, J.-M.; Temsamani, J. Enhanced Delivery of Doxorubicin into the Brain via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity. Mol. Pharmacol., 2000, 296(1), 124-131.
15. Stalmans, S.; Wynendaele, E.; Bracke, N.; Gevaert, B.; D'Hondt, M.; Peremans, K.; Burvenich, C.; De Spiegeleer, B. Chemical-Functional Diversity in Cell-Penetrating Peptides. PLOS ONE, 2013, 8(8), e71752.
16. Henriques, S.T.; Melo, M.N.; Castanho, M.A.R.B. Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem. J., 2006, 399, 1-7.
17. Palm, C.; Netzereab, S.; Hällbrink, M. Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects. Peptides, 2006, 27(7), 1710-1716.
18. Holm, T.; Netzereab, S.; Hansen, M.; Langel, Ü.; Hällbrink, M. Uptake of cell-penetrating peptides in yeasts. Febs Lett., 2005, 579(23), 5217-5222.
19. Wada, S.-i.; Tsuda, H.; Okada, T.; Urata, H. Cellular uptake of Aib-containing amphipathic helix peptide. Bioorg. Med. Chem. Lett., 2011, 21(19), 5588-5691.
20. Bikker, F.J.; Kaman-van Zanten, W.E.; de Vries-van de Ruit, A.- M.B.C.; Voskamp-Visser, I.; van Hooft, P.A.V.; Mars-Groenendijk, R.H.; de Visser, P.C.; Noort, D. Evaluation of the Antibacterial Spectrum of Drosocin Analogues. Chem. Biol. Drug Des., 2006, 68(3), 148-153.
21. Knappe, D.; Cassone, M.; Nollmann, F.I.; Otvos, L. Jr.; Hoffmann, R. Hydroxyproline substitutions stabilize non-glycosylated drosocin against serum proteases without challenging its antibacterial activity. Protein Pept. Lett., 2013, 21(4), 321-9.
22. Vergote, V.; Van Dorpe, S.; Peremans, K.; Burvenich, C.; De Spiegeleer, B. In vitro metabolic stability of obestatin: Kinetics and identification of cleavage products. Peptides, 2008, 29(10), 1740-1748.
23. Vergote, V.; Bodé, S.; Peremans, K.; Vanbree, H.; Baert, B.; Slegers, G.; Burvenich, C.; De Spiegeleer, B. Analysis of iodinated peptides by LC-DAD/ESI ion trap mass spectrometry. J. Chromatogr. B, 2007, 850(1-2), 213-220.
24. Vergote, V.; Baert, B.; Vandermeulen, E.; Peremans, K.; van Bree, H.; Slegers, G.; Burvenich, C.; De Spiegeleer, B. LC-UV/MS characterization and DOE optimization of the iodinated peptide obestatin. J. Pharmaceut. Biomed., 2008, 46(1), 127-136.
25. Patlak, C.S.; Blasberg, R.G.; Fenstermacher, J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cerebr. Blood F. Met., 1983, 3(1), 1-7.
26. Gjedde, A. High-affinity and low-affinity transport of D-glucose from blood to brain. J. Neurochem., 1981, 36(4), 1463-1471.
27. Triguero, D.; Buciak, J.; Pardridge, W.M. Capillary depletion method for quantification of blood-brain-barrier transport circulating peptides and plasma-proteins. J. Neurochem., 1990, 54(6), 1882-1888.
28. Gutierrez, E.G.; Banks, W.A.; Kastin, A.J. Murine tumor-necrosisfactor- alpha is transported from blood to brain in the mouse. J. Neuroimmunol., 1993, 47(2), 169-176.
29. Banks, W.A.; Kastin, A.J. Quantifying carrier-mediated transport of peptides from brain to the blood. Method. Enzymol., 1989, 168, 652-660.
30. Svenson, J.; Vergote, V.; Karstad, R.; Burvenich, C.; Svendsen, J. S.; De Spiegeleer, B. Metabolic Fate of Lactoferricin-Based Antimicrobial Peptides: Effect of Truncation and Incorporation of Amino Acid Analogs on the In vitro Metabolic Stability. J. Pharmacol. Exp. Ther., 2010, 332(3), 1032-1039.
31. Rau, C.-S.; Chang, W.-N.; Lin, Y.-C.; Lu, C.-H.; Liliang, P.-C.; Su, T.-M.; Tsai, Y.-D.; Chang, C.-J.; Lee, P.-Y.; Lin, M.-W.; Cheng, B.-C. Brain abscess caused by aerobic Gram-negative bacilli: clinical features and therapeutic outcomes. Clin. Neurol. Neurosur., 2002, 105(1), 60-65.
32. Stins, M.F.; Badger, J.; Kim, K.S. Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb. Pathogenesis, 2001, 30(1), 19-28.
33. Ribes, S.; Regen, T.; Meister, T.; Tauber, S.C.; Schütze, S.; Mildner, A.; Mack, M.; Hanisch, U.-K.; Nau, R. Resistance of the brain to Escherichia coli K1 infection depends on MyD88 signaling and the contribution of neutrophils and monocytes. Infect. Immun., 2013, 81(5), 1810-1819.